Belite Bio (BLTE) announced that the Center for Drug Evaluation of China’s National Medical Products Administration, NMPA, has agreed to accept the New Drug Application, NDA, with priority review for Tinlarebant for the treatment of Stargardt disease based on the interim analysis results from the Phase 3 DRAGON trial. “Having China NMPA agreed to review the NDA based on interim Phase 3 data is a remarkable milestone for Belite Bio and the Stargardt community,” said Dr. Tom Lin, Chairman and CEO of Belite Bio. “This milestone underscores the strength of the program and the urgent need for therapies in this devastating disease, where no approved treatment options exist. This achievement positions Belite Bio to advance Tinlarebant through the final stages of development and, if successful, bring the first treatment to people living with Stargardt disease.”
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BLTE:
- Belite Bio price target lowered to $98 from $100 at H.C. Wainwright
- Promising Outlook for Belite Bio, Inc. Amidst Phase 3 Success and Strong Financial Position
- Belite Bio completes Phase 3 DRAGON trial of Tinlarebant
- Belite Bio announces up to $250M upsized private placement financing
- Belite Bio Secures $125 Million in PIPE Financing with Potential for More